COVID-19 in Patients With Renal Cell Carcinoma in the Russian Federation

Tsimafeyeu, Ilya; Алексеева, Г. Н.; Berkut, M.; Носов, А. К.; Myslevtsev, Igor; Andrianov, A.N.; Semenov, Andrey; Borisov, Pavel; Zukov, Ruslan; Goutnik, Vadim; Савчук, С А; Volkova, Maria; Mukhina, M.

doi:10.1016/j.clgc.2020.07.007

Cited by 12 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the available retrospective studies have once again observed no increase in the severity or mortality of a COVID-19 infection within patients with RCC, 12 including those receiving ICI. 108 109 In regard to systemic therapeutic approaches, no available evidence suggests that the use of ICI worsens the risk or severity of a COVID-19 infection and therefore standard guideline-based approaches to treatment remain recommended. 110 However, it is worth re-emphasizing current standards of care including the use of pembrolizumab plus axitinib based on KEYNOTE-426 111 and nivolumab plus ipilimumab based on CheckMate 214 112 led to 27% and 29% of patients, respectively, requiring ≥40 mg/day oral prednisone doses equivalents due to irAEs that included pneumonitis.…”

Section: Rcc-specific Clinical Considerations Regarding Sars-cov-2 and Ici Usementioning

confidence: 99%

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

Switzer

Haanen

Lorigan

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.

show abstract

Section: Rcc-specific Clinical Considerations Regarding Sars-cov-2 and Ici Usementioning

confidence: 99%

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

Switzer

Haanen

Lorigan

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…Russia, Kazakhstan, and Belarus are countries of the Eurasian Economic Union with upper‐middle‐income economies. In 2015, the largest absolute number of new cases of kidney cancer was diagnosed in Russia (22 846) comparing with Kazakhstan (1104) and Belarus (2261) 1‐4 . The European age‐standardized incidence rates per 100 000 population were 9.77, 6.05, and 14.8, respectively.…”

Section: Introductionmentioning

confidence: 99%

Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Real‐world data describing outcomes of treatment among metastatic renal cell carcinoma (mRCC) patients are limited and heterogeneous. Aim RENSUR3 registry study assessed real‐world data on the use of therapies in mRCC and overall survival (OS) in Russia, Kazakhstan, and Belarus. Methods Patients were included in the retrospective multicenter registry study. To be eligible, patients were required to have mRCC diagnosed from January 2015 to January 2016. Anonymized data were collected through an online registry. The outcomes of interest were patient characteristics, treatment patterns, and OS. Results 1094 mRCC patients were identified. Mean age was 62.3 (SD, 11.2) years. Four hundred and forty‐four (41%) patients were 65 years and older. Primary tumor has not been removed in 503 (46%) patients. Subtype of RCC based on WHO classification (clear‐cell or other) has been reported in 402 (37%) patients. In total, 595 (54.4%) patients received systemic therapy for metastatic disease. 58% of elderly patients (≥65) were not treated compared to 37% of younger patients. Cytokines and targeted therapy were used in 298 (50.1%) and 297 (49.9%) of 595 treated patients, respectively. Median OS was 11.9 months (95% CI 10.9‐12.9). The 1‐ and 3‐year OS rates were 49.6% and 19.3%. Conclusions Half of patients received no systemic therapy or had only cytokines for mRCC in Russia, Kazakhstan, and Belarus, which doubtless negatively affected OS in this population. Novel therapies should be considered as life prolonging and a priority.

show abstract

“…KIRC and KIRP) of renal cell carcinoma (RCC), which is the most common (85%) malignant kidney tumor. This might suggest a potential mechanism underlying the links of COVID-19 and RCC observed in a previous epidemiological study [5]. The three mQTL-CpGs were separately located in gene body regions of NS3 binding protein (NS3BP), FYVE and coiled-coil domain autophagy adaptor 1 (FYCO1), and transaldolase 1 (TALDO1) (Supplementary Tables S3 and S4).…”

mentioning

confidence: 59%

An integrated genetic‐epigenetic analysis shed light on the mechanisms linking coronavirus disease 2019 (COVID‐19) and cancer

Dong

2021

Cancer Communications

View full text Add to dashboard Cite

An integrated genetic-epigenetic analysis shed light on the mechanisms linking coronavirus disease 2019 (COVID-19) and cancerDear editor, The Coronavirus disease 2019 (COVID-19) is an emerging disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1,2]. It has spread rapidly across the world and caused a global health emergency. As of 10 February 2021, COVID-19 has caused 2,333,446 deaths worldwide. The majority of COVID-19 deaths had comorbidities including cancer [1,2]. Notably, a recent study suggested that cancer was the only independent risk factor for death of COVID-19 patients among common comorbidities [3]. Moreover, cancer patients are more susceptible to SARS-CoV-2 infection than noncancer individuals due to their specific immunosuppressive state [3]. Despite the links between COVID-19 and cancer, the genetic and epigenetic mechanisms underlying these links remain unclear. Thus far, only genetic and epigenetic variants within three COVID-19 receptors,

show abstract

COVID-19 in Patients With Renal Cell Carcinoma in the Russian Federation

Cited by 12 publications

References 1 publication

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors

Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry

An integrated genetic‐epigenetic analysis shed light on the mechanisms linking coronavirus disease 2019 (COVID‐19) and cancer

Contact Info

Product

Resources

About